Friday, 31 Oct 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • VIDEO
  • House
  • White
  • ScienceAlert
  • Trumps
  • Watch
  • man
  • Health
  • Season
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Health and Wellness > Sedative medetomidine, or ‘dex,’ complicates battle against fentanyl
Health and Wellness

Sedative medetomidine, or ‘dex,’ complicates battle against fentanyl

Last updated: May 1, 2025 4:30 am
Share
Sedative medetomidine, or ‘dex,’ complicates battle against fentanyl
SHARE

The era of “tranq,” the powerful veterinary tranquilizer xylazine that has been prevalent in the illicit drug supply, may be coming to an end. However, a new dangerous sedative called medetomidine is quickly taking its place. Cities like Philadelphia, Pittsburgh, Chicago, and San Francisco have reported a rise in overdoses involving medetomidine in the past year.

In Philadelphia, reports of medetomidine have surged. Initially, when the city began testing for the substance in May 2024, it was found in 29% of fentanyl samples. Six months later, the prevalence of medetomidine had tripled to 87%, while xylazine had decreased from 100% to 42%.

For years, illegal drug suppliers in the U.S. have been cutting fentanyl with sedatives like xylazine to make it more cost-effective. Many drug users have unknowingly encountered xylazine in substances marketed as fentanyl, while others have actively sought it despite its powerful sedative effects. As law enforcement has cracked down on xylazine, medetomidine, a pharmacologically active form known as dexmedetomidine or “dex,” has swiftly taken its place.

Medetomidine is causing severe health complications among drug users, even more so than xylazine. Overdoses involving medetomidine result in low heart rates and profound sedation, making overdose reversals more challenging. Additionally, withdrawal symptoms from medetomidine can be life-threatening, with the sympathetic nervous system causing elevated heart rate and blood pressure that can harm vital organs like the heart and brain.

Unlike xylazine withdrawal, which is often mild, medetomidine withdrawal is characterized by heightened heart rate and blood pressure. Medetomidine belongs to the same family of medications as xylazine and clonidine, a common antihypertensive medication used to treat ADHD and pain.

See also  Rachel Maddow 'Veering Into Diva Territory' Amid Battle With MSNBC Heads

Although formulations of medetomidine are used in veterinary settings, they are also used in humans under the brand name Precedex for sedation. The rapid spread of medetomidine in Pennsylvania’s drug supply occurred after the state cracked down on xylazine by classifying it as a Schedule III controlled substance.

Nabarun Dasgupta, a pharmacoepidemiologist at the University of North Carolina, believes the rise of dexmedetomidine was inevitable. Legislation targeting xylazine created a demand for a replacement with similar properties, leading to the emergence of medetomidine in the illicit drug market.

The presence of medetomidine in the drug supply adds a layer of uncertainty to the ongoing U.S. overdose epidemic. While overall trends show a decrease in the death toll from overdoses, medetomidine, like xylazine, does not respond to naloxone, the medication used to reverse opioid overdoses.

Efforts to crack down on medetomidine could potentially limit access to a medication critical for many healthcare providers’ daily responsibilities. As the drug landscape continues to evolve, addressing the rise of dangerous sedatives like medetomidine is crucial to preventing further harm in the ongoing opioid crisis. The increasing prevalence of medetomidine in the drug supply has posed new challenges for health providers and researchers alike. While the death rate may be decreasing, the presence of medetomidine has complicated treatment, overdose response, and post-overdose care.

Medetomidine withdrawal has proven to be particularly challenging, with potentially life-threatening symptoms that require medical intervention. In comparison to opiate withdrawal, medetomidine withdrawal often necessitates a higher level of care and specialized treatment. Treatment typically involves a combination of medications such as short-acting opioids for pain relief, alpha-2 agonists like clonidine, anti-nausea drugs, and sedatives to manage symptoms like high blood pressure.

See also  Physicists are waging a cosmic battle over the nature of dark energy

Despite the difficulties associated with medetomidine withdrawal, there may be a silver lining in the form of reduced skin complications. Unlike xylazine, which is known to cause deep skin wounds and necrosis, medetomidine does not have the same reputation for causing such issues.

In response to the growing prevalence of medetomidine in the drug supply, public health officials, researchers, and harm reduction advocates have taken steps to address the challenges it presents. Forums and conferences have been held to discuss strategies for treating medetomidine withdrawal, and some states have issued warnings about its dangers. Companies like BTNX have also developed test strips to detect the presence of medetomidine in substances, providing a valuable tool for harm reduction efforts.

Dr. Dasgupta, a researcher at the University of North Carolina, emphasizes the heightened dangers posed by dexmedetomidine for drug users. Its powerful sedative properties increase the risk of overdoses and leave individuals vulnerable to dangerous situations while under its influence. The similarities between xylazine and dexmedetomidine in appearance highlight the importance of caution and awareness when dealing with these substances.

Overall, the rise of medetomidine in the drug supply underscores the need for continued vigilance and innovation in addressing the evolving challenges of substance use and addiction. By staying informed, collaborating with experts, and utilizing available resources, healthcare providers and communities can better respond to the complexities of medetomidine and other emerging substances in the drug landscape.

TAGGED:battlecomplicatesdexfentanylmedetomidineSedative
Share This Article
Twitter Email Copy Link Print
Previous Article Pam Bondi’s Bold Trump Stat Turns Heads, And Not In A Good Way Pam Bondi’s Bold Trump Stat Turns Heads, And Not In A Good Way
Next Article Turns out, every bug is horrifying when you zoom in x80 Turns out, every bug is horrifying when you zoom in x80
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

Serial California Tesla road rage driver Nathaniel Radimak released from prison — less than a year into 5-year sentence

A Tesla driver known for his road rage incidents on California highways has been released…

August 29, 2024

Warner Bros. Discovery and CJ ENM Form Strategic Partnership to Expand K-Content Reach

Warner Bros. Discovery and CJ ENM have announced an extensive multi-year collaboration that will deliver…

October 15, 2025

Free Printable 2025-2026 Teacher Calendar

Are you ready for the ultimate teacher calendar for the year 2025-2026? Look no further…

June 10, 2025

New York City Shows to See Right Now

As we delve into the world of art and architecture this week, we are presented…

May 27, 2025

Investigative Journalist Joel Gilbert – the Man Behind the Letitia James Files: ’s “Letitia Files” Become National News with Criminal Referral – And More Is Coming Out Soon! |

Dark days ahead for Letitia James By Joel Gilbert – the investigative journalist behind the…

April 16, 2025

You Might Also Like

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests
Health and Wellness

Remission achievable for 1 in 3 Indian diabetics through intensive app-based lifestyle program, study suggests

October 31, 2025
Once Again A Blood Pressure Medication Recall For Cancer Concerns
Health and Wellness

Once Again A Blood Pressure Medication Recall For Cancer Concerns

October 31, 2025
IVF research, FDA vouchers, dementia: Morning Rounds
Health and Wellness

IVF research, FDA vouchers, dementia: Morning Rounds

October 31, 2025
Nearly 1 in 5 urinary tract infections linked to contaminated meat
Health and Wellness

Nearly 1 in 5 urinary tract infections linked to contaminated meat

October 31, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?